Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].

Mirza, M R; Coleman, R L; González-Martín, A; Moore, K N; Colombo, N; Ray-Coquard, I; Pignata, S.

Afiliação

Mirza MR; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: Mansoor.Raza.Mirza@regionh.dk.
Coleman RL; Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
González-Martín A; Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
Moore KN; Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, USA.
Colombo N; Division of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, Italy.
Ray-Coquard I; Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G.Pascale, Napoli, Italy.

Ann Oncol ; 32(8): 1066-1067, 2021 Aug.

Article em En | MEDLINE | ID: mdl-34090767

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article